Daiichi Sankyo Receives Approval for the Use of Inavir® to Prevent Influenza

For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Corporate Officer, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 http://www.daiichisankyo.com Daiichi Sankyo Receives Approval for the Use of Inavir® to Prevent Influenza Tokyo, Japan (December 20, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that it received approval in Japan to market Inavir® Dry Powder Inhaler 20mg (generic name: Laninamivir Octanoate Hydrate) for the prevention of influenza in both adults and children. Inavir® is a long-acting neuraminidase inhibitor developed by Daiichi Sankyo which is manufactured in Japan. The drug was originally launched in Japan for treatment of influenza A and B in October 2010. Daiichi Sankyo has great expectations for the additional influenza prevention indication for Inavir®, which will provide an additional option for the public to protect themselves against the influenza virus and allow Daiichi Sankyo to further contribute to the health of society. Product overview Drug name Inavir® Dry Powder Inhaler 20mg Date of approval for partial changes December 20, 2013 Indications and usage (additional approval underlined) Treatment and prevention of influenza A and B viruses Dosage and administration (additional approval underlined) 1. For treatment of the influenza virus Adults: A single inhaled dose of 40 mg of laninamivir octanoate Children: If less than 10 years old, a single inhaled dose of 20 mg of laninamivir octanoate If 10 years old or older, a single inhaled dose of 40 mg. 2. For prevention of the influenza virus Adults and children over 10 years of age: Daily single inhaled dosage of 20 mg of laninamivir octanoate for two days

The release as fetched from its publisher. daiichisankyo.com ↗